Updated Jul 8, 9:51 PM · 60 sources analyzed
Key Takeaways
Keros Therapeutics terminated its Phase 2 PAH program KER-012, removing a key pipeline asset without disclosing any data.
United Therapeutics' Phase 3 ralinepag PAH trial also terminated, a pipeline setback despite strong commercial position in the indication.
Today's sources are dominated by registry status changes with no efficacy data; no approvals, deals, or major readouts occurred.
📉 Loser
Keros Therapeutics — Phase 2 PAH program KER-012 terminated with no data disclosed, shrinking the pipeline without explanation
🔭 Watch Next
GREEN study (glenzocimab in acute ischemic stroke) and Otsuka's short-course TB regimen trial are both newly completed — efficacy data presentations at upcoming neurology and infectious disease conferences in late 2026 are the next material events to watch from today's sources.
Keros Therapeutics Terminates PAH Program KER-012
Keros Therapeutics has terminated its Phase 2 TROPOS study of KER-012 in pulmonary arterial hypertension (PAH), a severe progressive lung vascular disease, according to a ClinicalTrials.gov status update. The trial was a double-blind, randomized, placebo-controlled study evaluating KER-012 on top of standard background therapy, and its termination removes the asset from Keros's pipeline without any efficacy data being disclosed publicly. PAH is a crowded but high-value indication, and the loss of a differentiated mechanism leaves Keros with a narrower pipeline footprint at a time when investors are scrutinizing the company's path forward.
ClinicalTrials.gov ↗Keros Therapeutics
KER-012 in Pulmonary Arterial Hypertension (PAH)
The TROPOS study (NCT05975905) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released publicly in connection with this termination.
Why it matters
A Phase 2 termination without disclosed data is rarely a good sign — it typically signals either safety issues, futility, or a strategic pivot. Investors will want to understand whether this was a data-driven decision or a resource allocation choice, as the answer materially changes the risk profile of Keros's remaining pipeline.
What to watch
Watch for a company statement or investor call explaining the reason for termination and any reallocation of resources to other pipeline assets, expected imminently.
United Therapeutics
Ralinepag in Pulmonary Arterial Hypertension (PAH)
The ADVANCE CAPACITY Phase 3 study (NCT04084678), which was evaluating ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) by cardiopulmonary exercise testing, has been marked Terminated on ClinicalTrials.gov. No efficacy data have been released in connection with this termination.
Why it matters
United Therapeutics already dominates PAH commercially, so this termination is more of a pipeline pruning event than an existential threat — but the loss of an oral IP prostacyclin receptor agonist at Phase 3 stage limits the company's long-term differentiation against competitors like Johnson & Johnson (Uptravi) and Merck.
What to watch
Watch for any United Therapeutics guidance on whether ralinepag development continues in other PAH subpopulations or is formally discontinued, and whether the company accelerates other pipeline assets to fill the gap.
Novartis
Alpelisib + nab-paclitaxel in Advanced Triple-Negative Breast Cancer (TNBC) with PIK3CA mutation or PTEN loss
The Phase 3 study (NCT04251533) evaluating alpelisib combined with nab-paclitaxel in advanced TNBC with PIK3CA mutation or PTEN loss has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data have been disclosed in connection with this termination.
Why it matters
Alpelisib's utility in TNBC was always a stretch mechanistically, and this termination is consistent with the broader difficulty of PI3K inhibition in triple-negative settings. The more important question for Novartis is whether the safety profile of alpelisib (glucose toxicity remains a significant clinical burden) limits its competitiveness even in approved indications.
What to watch
Watch for any Novartis commentary on alpelisib's commercial trajectory and whether the company is investing in next-generation PI3K inhibitors with improved tolerability to sustain this franchise.
Syndax Pharmaceuticals
Revumenib in Colorectal Cancer and Other Solid Tumors
The Phase 1/2 study of revumenib in colorectal cancer and other solid tumors (NCT05731947) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released publicly in connection with this termination.
Why it matters
Revumenib earned accelerated approval in acute leukemia based on strong menin inhibition biology in NPM1-mutant and KMT2A-rearranged disease — but translating that signal into solid tumors was always speculative. This termination is not surprising scientifically, but it removes a potential upside narrative that some investors may have been pricing in.
What to watch
Watch for Syndax's next update on revumenib's confirmatory hematology trial and any Phase 3 data readouts that will determine whether the accelerated approval converts to full approval.
The TROPOS study (NCT05975905) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released publicly in connection with this termination.
Why it matters
KER-012's exit from PAH removes a potential differentiator in a competitive indication and narrows Keros's clinical pipeline, raising questions about the company's near-term catalysts.
Analysis
A Phase 2 termination without disclosed data is rarely a good sign — it typically signals either safety issues, futility, or a strategic pivot. Investors will want to understand whether this was a data-driven decision or a resource allocation choice, as the answer materially changes the risk profile of Keros's remaining pipeline.
What to watch
Watch for a company statement or investor call explaining the reason for termination and any reallocation of resources to other pipeline assets, expected imminently.
The ADVANCE CAPACITY Phase 3 study (NCT04084678), which was evaluating ralinepag's effect on exercise capacity via peak oxygen consumption (VO2 max) by cardiopulmonary exercise testing, has been marked Terminated on ClinicalTrials.gov. No efficacy data have been released in connection with this termination.
Why it matters
A Phase 3 termination for ralinepag in PAH is a meaningful setback for United Therapeutics' oral prostacyclin pipeline ambitions, though the company retains a strong commercial franchise in PAH with existing approved products.
Analysis
United Therapeutics already dominates PAH commercially, so this termination is more of a pipeline pruning event than an existential threat — but the loss of an oral IP prostacyclin receptor agonist at Phase 3 stage limits the company's long-term differentiation against competitors like Johnson & Johnson (Uptravi) and Merck.
What to watch
Watch for any United Therapeutics guidance on whether ralinepag development continues in other PAH subpopulations or is formally discontinued, and whether the company accelerates other pipeline assets to fill the gap.
The first-in-human Phase 1/2 study of SAR443579 (NCT05086315) across multiple hematologic malignancies has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data have been released publicly in connection with this termination.
Why it matters
Termination of an early-stage hematologic oncology asset at Phase 1/2 signals that SAR443579 did not meet the bar required to advance, thinning Sanofi's oncology bench at a time when the company is working to rebuild its cancer pipeline.
Analysis
For a large-cap like Sanofi, any single early-phase termination is manageable, but the pattern of pipeline attrition in oncology matters — investors evaluating Sanofi's long-term oncology ambitions will want to see durable replacement assets rather than relying on the Dupixent franchise indefinitely.
What to watch
Watch for Sanofi's next oncology pipeline update, likely at a major investor day or medical conference, to gauge how they plan to replenish early-stage hematology assets.
The Phase 3 study (NCT04251533) evaluating alpelisib combined with nab-paclitaxel in advanced TNBC with PIK3CA mutation or PTEN loss has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data have been disclosed in connection with this termination.
Why it matters
TNBC with PIK3CA alterations remains a difficult-to-treat population with few targeted options, and the failure to advance this combination forecloses what would have been a meaningful label expansion for alpelisib beyond its approved HR+/HER2- breast cancer indication.
Analysis
Alpelisib's utility in TNBC was always a stretch mechanistically, and this termination is consistent with the broader difficulty of PI3K inhibition in triple-negative settings. The more important question for Novartis is whether the safety profile of alpelisib (glucose toxicity remains a significant clinical burden) limits its competitiveness even in approved indications.
What to watch
Watch for any Novartis commentary on alpelisib's commercial trajectory and whether the company is investing in next-generation PI3K inhibitors with improved tolerability to sustain this franchise.
The Phase 1/2 study of revumenib in colorectal cancer and other solid tumors (NCT05731947) has been marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released publicly in connection with this termination.
Why it matters
Revumenib's termination in solid tumors confirms that its activity is likely confined to the hematologic malignancy setting where it received approval, narrowing the commercial expansion story for Syndax.
Analysis
Revumenib earned accelerated approval in acute leukemia based on strong menin inhibition biology in NPM1-mutant and KMT2A-rearranged disease — but translating that signal into solid tumors was always speculative. This termination is not surprising scientifically, but it removes a potential upside narrative that some investors may have been pricing in.
What to watch
Watch for Syndax's next update on revumenib's confirmatory hematology trial and any Phase 3 data readouts that will determine whether the accelerated approval converts to full approval.
Glenzocimab Evaluated in Phase 2/3 Ischemic Stroke Reperfusion Trial (GREEN Study)
The GREEN study (NCT05559398), a Phase 2/3 trial of glenzocimab — a glycoprotein VI (GPVI) inhibitor targeting platelet activation — combined with endovascular therapy (EVT) for acute ischemic stroke, has been marked Completed on ClinicalTrials.gov; no efficacy data have been publicly disclosed in connection with this status update.
Why it matters
If glenzocimab demonstrates a clean safety profile alongside EVT without increasing bleeding risk, it could validate GPVI as a druggable target in the acute stroke adjunct space — a niche with very few approved agents.
Analysis
The GREEN study completion is worth monitoring because the field of adjunctive antithrombotic therapy in EVT-treated stroke is essentially empty — any signal of benefit without hemorrhagic transformation would be clinically meaningful and commercially interesting. The absence of disclosed data means the investment story remains binary until results are published.
What to watch
Watch for publication or conference presentation of GREEN study efficacy and safety data, expected at a neurology or stroke meeting such as the International Stroke Conference or ESC, likely in late 2026.
Otsuka's Short-Course TB Regimen (OPC-167832 + Delamanid + Bedaquiline) Completes Phase 2
Otsuka's Phase 2 trial (NCT05221502) comparing a 17-week regimen of OPC-167832 with delamanid and bedaquiline against the standard 6-month regimen for drug-susceptible tuberculosis has been marked Completed; outcome data have not been publicly disclosed.
Why it matters
A validated shorter-course all-oral TB regimen without rifamycins could address a significant global health need and open commercial opportunities in TB-endemic markets, particularly given that standard 6-month therapy is a major driver of non-adherence and acquired resistance.
Analysis
The completion of this study is a meaningful step for Otsuka's TB ambitions — a 17-week regimen beating 6-month standard of care would be a genuinely differentiated outcome in a space where WHO has been pushing hard for shorter, simpler regimens. Investors in Otsuka or partners watching the TB drug development space should await the efficacy readout closely.
What to watch
Watch for Otsuka's disclosure of primary efficacy data — specifically culture conversion rates and relapse-free outcomes — expected at a global TB or infectious disease conference in 2026 or early 2027.
Sangamo CAR-Treg Cell Therapy Completes Phase 1/2 in Kidney Transplant Recipients
Sangamo Therapeutics' Phase 1/2 study of TX200-TR101 — a chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy designed to promote immune tolerance in living donor kidney transplant recipients — has been marked Completed on ClinicalTrials.gov; no efficacy or safety outcome data have been publicly disclosed.
Why it matters
CAR-Treg therapy for transplant tolerance is one of the most scientifically compelling frontiers in immunology — if TX200-TR101 shows durable kidney graft tolerance with immunosuppression reduction, it could establish a proof-of-concept for engineered regulatory T cells across autoimmune and transplant indications.
Analysis
Sangamo has had a difficult few years with its gene editing pipeline, and TX200-TR101 represents an important proof-of-concept moment for the CAR-Treg platform. The study completion means results should be forthcoming — and given the novelty of the biology, even safety-and-feasibility data with hints of tolerogenic activity could re-energize investor interest in this approach.
What to watch
Watch for Sangamo's publication or presentation of TX200-TR101 safety, immunosuppression tapering, and any graft tolerance biomarker data at a transplantation or immunology congress in late 2026.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.